Top 20 Life Science Startup Investors in Norway in May 2026

Portfolio highlights

• Two — Buy Now, Pay Later for your business customers. Two makes it easy and safe to offer invoice as a payment method on your e-commerce site.
• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Kongsberg Ferrotech — Kongsberg Ferrotech offers game-changing robotic services for inspection, repair, and maintenance (IRM) of underwater installations

Portfolio highlights

• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Porterbuddy — They are the gang that delivers to your door the same day you order in the online store.Porterbuddy'​ is a logistics platform that provides efficient and customer-centric, last-mile delivery of products.
• Damora Therapeutics — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.

Portfolio highlights

• Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
• Spica Therapeutics — Spica Therapeutics is a pioneering biotech company dedicated to transforming macrophage biology into breakthrough therapies for patients across multiple therapeutic areas. Leveraging its proprietary functional macrophage fingerprinting technology, Spica identifies and selectively targets disease-relevant macrophage sub
• Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.

Portfolio highlights

• Filics — A scalable transport solution for standardized load carriers with a minimum energy footprint
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.
• Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.

Portfolio highlights

• NodThera — NodThera is a biotechnology company treating chronic diseases by targeting inflammation at its source.
• Biosyntia — Biosyntia is a biotech startup within synthetic biology and metabolic engineering. We develop biocatalysts at an unprecedented speed and efficiency by employing our patent pending high-throughput screening technology.By developing tailored processes based on biocatalysis, Biosyntia enables production of complex chemical compounds byfermentation. Biocatalysis may substantially reduce both production costs and environmental impact compared to other processes such as chemical synthesis. We partner with manufacturers of fine chemical compounds (flavors, fragrances, APIs, pigments, additives, intermediates, and more) in order to establish more sustainable manufacturing processes for a greener tomorrow.Biosyntia is located at the Novo Nordisk Foundation (NNF) Center for Biosustainability in Hørsholm, 25 kilometers north of Copenhagen.
• T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

Portfolio highlights

• APIM Therapeutics — APIM Therapeutics is based on an original discovery by Prof. Marit Otterlei and co-inventors at the Department of Cancer Research and Molecular Medicine at NTNU (Trondheim, Norway). The company is currently developing proprietary peptide drugs targeting PCNA (Proliferating Cell Nuclear Antigen), a key DNA repair protein regulating cellularresponses to DNA damage and stress.
• Zelluna Immunotherapy — Zelluna Immunotherapy AS is a privately owned biopharmaceutical company focused on the development of TCR based immunotherapies.
• Accession Therapeutics — Accession Therapeutics’ elegant Trocept platform has potential to treat some of the most intractable and widespread forms of cancer. Based in Oxford, UK, it is developing a pipeline of products to the early clinical trial stage. Led by Bent Jakobsen, PhD FMedSci, a pioneer of T cell receptor therapy for cancer, the team is highly experienced intaking immuno-oncology products to the clinic. Accession Therapeutics’ Trocept technology is based on over a decade’s work and has generated exceptional preclinical data.Accession Therapeutics’ proprietary technology incorporates cancer-tropic viruses, the first time that viruses have been genetically modified to exclusively target cancer cells. As non-cancerous cells are not targeted by Trocept, systemic toxicity is eliminated meaning the drugs can be delivered intravenously and traffic to the tumour. Trocept’s highly potent and local activity gives it potential in some of the hardest to treat and most widespread forms of cancer. This includes breast, cervical, colorectal, gastric, head and neck, lung, oral, ovarian and pancreatic cancer.

Portfolio highlights

• Nomono — Capture studio-quality podcasts with immersive 3D audio. Get professional mics, AI editing, and cloud storage in one system. Start your free trial today.
• Hystar — Hystar develops polymer electrolyte membrane electrolyzers designed for large-scale green hydrogen production. Founded in 2020, Hystar's technology uses a unique cell design and process architecture that provides the ability to reduce electricity consumption and increase hydrogen output, enabling professionals to tackle various criticalenergy challenges and having the potential to reduce greenhouse gas emissions.
• Hydrogen Mem-Tech — Hydrogen Mem-Tech aim is to make the green shift happen through our state-of-the-art hydrogen separation technology with carbon capture.

Portfolio highlights

• SeaForester — Restoring the forgotten forests in our ocean.
• Ocean Rainforest — Ocean Rainforest offer a collection of premium fully-traceable seaweed products, mostly for food and cosmetic producers.
• Seaweed Solutions — Seaweed Solutions AS is one of Europe's largest seaweed farmers based in Norway. Our experience in seaweed farming dates back to 1978.

Portfolio highlights

• Agribuddy — Management of agricultural support application "AGRIBUDDY".
• CanopyLAB — CanopyLAB is an educational technology company located in Hvidovre, Greater Copenhagen, Denmark. We have built an AI-powered social learning platform for corporate training. Through personalization our platform enables all learners to realize their potential in a way that is fast, fun and future-proof. We call it "The Future of Learning-Delivered Today".We work on two verticals:1. The Canopy A social learning platform powered by AI A research-based social learning platform for developing competencies through individualized and adaptive learning experiences. It is designed with an integrated social network structure to enhance collaborative learning and built on strong Nordic learning principles.2. The LAB A learning community with provocative content Join our global learning community for youth. Take free courses, exchange ideas, gain new knowledge and practice competencies offered by 100 + pioneering NGOs in controversial and often neglected topics such as sexuality, sexual & reproductive rights, climate action, health, and the SDGs.CanopyLAB acquired Peruvian publishing startup Yopublico in April 2020.
• Destácame — Destacame is the first behavior-based credit score in Latin America.

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• CellFE — We transform the way cell therapies are manufactured to enable affordable advanced treatments for all.
• Lucid Scientific — Lucid Scientific is the maker of Resipher - the world's first handheld cell culture monitor to measure real-time oxygen consumption from inside an incubator.
• Vernal Biosciences — Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis.

Portfolio highlights

• Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.

Portfolio highlights

• Oumla — Secure, scalable blockchain infrastructure for businesses, enterprises, and governments to manage digital assets with ease and compliance.
• Hazen.ai — Enhance safety with our AI-powered camera, providing real-time monitoring and precise violation detection. This technology empowers authorities to enforce traffic laws effectively, ensuring safer roads for all.
• Stake — Thousands investors worldwide use Stake to access income-generating real estate deals in high-growth markets, starting from just USD 136

Portfolio highlights

• Delft IMP — Delft IMP (Intensified Materials Production) commercializes nanostructuring of particles using atomic and molecular layer deposition (ALD and MLD), based on the patented and publicized IP and know-how developed within the Product & Process Engineering (PPE) group at Delft University of Technology. Following various feasibility projects betweenindustry and university, Delft IMP was initiated end 2014 to truly commercialize the technology.
• Cytovation — Cytovation AS is a privately-held biotech company, specialising in dermatological diseases, based in Bergen, Norway.

Portfolio highlights

• Versor — Versor develops software necessary for true autonomous drone flight both indoors and outdoors, enabling complete automation of industrial drone operations. They believe this level of automation requires superior localization, which is particularly difficult to achieve indoors and in GPS-denied areas. By removing the need for pilots, entire fleetsof drones may be supervised remotely, enabling true scalability of drone operations across various applications.
• Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications

Portfolio highlights

• Aurora Analytica — AI-powered clinical intelligence for CROs. Country strategy, feasibility simulation, and trial intelligence in one platform. ESMO-published. EIC-selected. Norway.

Portfolio highlights

• Iris.ai — Augment expert knowledge by unifying complex enterprise data to empower next-gen AI agents & applications

Portfolio highlights

• Kure Cells — Kure Cells delivers innovative solutions in cell therapy, biotechnology, and clinical research to advance modern healthcare.

Portfolio highlights

• SciRhom — SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academicand industry scientists with profound experience in antibody development.
• Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
• TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.